rare disease

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

News

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

Topics • Strategy

After Pharma’s Patent Cliff

Top-Feature

Evonik Industries AG

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Immedica Pharma AB

SchüllerConsulting

rare disease

Immedica to Acquire Biopharma Company Marinus

Pfizer Doubles Dublin Biologicals Capacity

After Pharma’s Patent Cliff

Top-Feature

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Predictive Simulation in Pharma Production

Upcoming Virtual Events

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download

Newsletter & e-edition